Overview | Day 1 | Day 2 | Download Brochure

• New Approaches for RNAi Delivery
• Exploring Diverse Therapeutic Indications
• Addressing Safety and Manufacturing Concerns

DISTINGUISHED FACULTY

Evgenia Alpert, M.D., Ph.D., Quark
Pharmaceuticals Inc.
Mark Behlke, M.D., Ph.D., Integrated DNA Technologies
Johannes Freuhauf, M.D., Ph.D., Cequent Pharmaceuticals Inc.
Todd Kreutzian, Agilent Technologies
Robert J. Lee, Ph.D., Ohio State University
Zdravka Medarova, Ph.D., Massachusetts General Hospital
Ian McLachlan, Ph.D., Protiva
Biotherapeutics Inc.
Pieter Peeters, Ph.D., Johnson & Johnson Pharmaceutical Research and Development
Dmitry Samarsky Ph.D., RXi
Pharmaceuticals Corp.
Ansgar Santel, Ph.D., Silence Therapeutics AG
Mohan Sapru, Ph.D., Northwestern University
Thomas Singer, D.A.B.T., F. Hoffmann-La Roche AG
Eric Tien, Ph.D., Pfizer
Michael Templin, Ph.D., D.A.B.T., Nastech Pharmaceutical Co.
Jian Wu, M.D., Ph.D., University of
California – Davis Medical Center
Lei Yu, M.D., Ph.D., Nitto Denko Technical Corp.
John Zaia, M.D., Beckman Research Institute